Depyrogenated Sterile Empty Vials Market: Who Wins by 2033?

Glass Material Segment Dominance in the Depyrogenated Sterile Empty Vials Market

Among the material-based segmentation of the Depyrogenated Sterile Empty Vials Market, the glass sub-segment — specifically Type I borosilicate glass — maintains overwhelming revenue dominance, accounting for an estimated 72–75% of total market value in 2023. This dominance is not merely legacy inertia; it reflects the irreplaceable physicochemical properties of borosilicate glass that align with the chemical complexity and stability requirements of modern biologic and small-molecule injectables.

Type I borosilicate glass, defined under ISO 4802 and USP <660>, provides a coefficient of thermal expansion of approximately 3.3 × 10⁻⁶/°C, outstanding hydrolytic resistance (Hydrolytic Class I), and near-zero extractable and leachable profiles. These properties are critical for biologics such as monoclonal antibodies, peptide hormones, and oligonucleotide therapeutics, which are highly susceptible to protein adsorption, pH shifts, and ionic contamination. The depyrogenation step — typically executed via dry heat at temperatures exceeding 250°C for a validated dwell time — is technically compatible with glass but poses significant challenges for most thermoplastic alternatives, reinforcing glass's entrenched market position.

The 2 mL and 5 mL glass vial sub-segments collectively represent the highest volume categories, driven by unit-dose biologics, lyophilized injectables, and clinical trial material packaging. The 10 mL and 20 mL formats are gaining traction in oncology and immunology therapy segments, where multi-dose or concentrated formulations require larger containment volumes without sacrificing sterility assurance levels (SAL) of 10⁻⁶ or better.

Key players anchoring the glass segment include Gerresheimer, SCHOTT, and Stevanato Group, each of which operates vertically integrated manufacturing platforms that span glass tubing production, vial forming, coating, washing, and depyrogenation tunnel processing. Gerresheimer's pharmaceutical glass division, for instance, operates more than 20 production facilities globally, enabling regional supply security for multinational pharmaceutical clients. SCHOTT's FIOLAX tubing — widely regarded as the industry gold standard — provides the raw material base for a significant proportion of global parenteral glass vials, creating a deep upstream integration advantage.

Stevanato Group has distinguished itself through its EZ-fill ready-to-use format, which delivers pre-washed, depyrogenated, and sterile vials directly to pharmaceutical fill-finish lines, reducing in-house preparation burden and compliance risk for drug manufacturers. This value-added positioning commands premium pricing and is increasingly adopted by biotech companies prioritizing speed-to-market.

The glass segment's share, while dominant, is under modest long-term pressure from cyclic olefin copolymer (COC) and cyclic olefin polymer (COP) plastic vials, particularly in applications where break-resistance, weight reduction, or tungsten-free manufacturing is prioritized. However, the regulatory qualification burden of transitioning from glass to polymer — including full extractables and leachables (E&L) studies, compatibility profiling, and stability testing — means glass will retain its commanding market share at least through 2030. The segment's consolidation trend is also notable: top-four glass vial manufacturers now control an estimated 58–62% of global production capacity, signaling maturation at the supply tier even as end-user demand accelerates.

Key Market Drivers and Constraints Shaping the Depyrogenated Sterile Empty Vials Market

The Depyrogenated Sterile Empty Vials Market is propelled by a set of quantifiable, interconnected drivers that collectively define its above-average growth profile relative to the broader pharmaceutical packaging sector.

Biologics and biosimilars pipeline expansion is the most potent demand driver. As of 2024, the global biologic drug pipeline comprises more than 6,000 active candidates across clinical stages, with injectable formulations accounting for approximately 85% of biologic dosage forms. Each approved biologic typically requires between 5 million and 200 million primary packaging units annually, depending on indication prevalence and dosing frequency. This translates directly to sustained high-volume demand for sterile depyrogenated vials.

Vaccine manufacturing infrastructure, permanently expanded following the 2020–2022 COVID-19 vaccine mobilization, represents a structural rather than cyclical driver. Governments and multilateral agencies have committed to maintaining surge-capacity fill-finish facilities, with the CEPI (Coalition for Epidemic Preparedness Innovations) targeting 100-day vaccine development capability by 2025, which necessitates standing inventories of qualified sterile primary containers.

Regulatory stringency is simultaneously a driver and a constraint. Compliance with FDA 21 CFR Part 211, EU GMP Annex 1 (revised 2022), and WHO Good Manufacturing Practice guidelines mandates validated depyrogenation processes with documented endotoxin log-reduction of at least 3-log (i.e., 1,000-fold), raising entry barriers and favoring established certified manufacturers.

The primary constraint is raw material supply concentration. Borosilicate glass tubing production is dominated by a small number of global suppliers, creating periodic supply tightening. Energy cost volatility — given that glass melting furnaces operate continuously at 1,500°C — directly impacts manufacturing margins. Additionally, the capital expenditure required for compliant depyrogenation tunnel systems (typically $1.5 million–$4 million per unit) limits capacity expansion agility for smaller manufacturers.

Labor and cleanroom operating costs in regulated markets continue to escalate, with ISO Class 7 and Class 5 environment operating costs estimated at $500–$1,200 per square meter annually, creating ongoing pressure on cost structures and pushing production toward lower-cost geographies in Asia.

Competitive Ecosystem of the Depyrogenated Sterile Empty Vials Market

The competitive landscape of the Depyrogenated Sterile Empty Vials Market is characterized by a mix of vertically integrated glass specialists, diversified life sciences distributors, and specialty contract packaging entities. The following profiles outline the strategic positioning of key participants:

• Gerresheimer: A global leader in pharmaceutical glass and plastic packaging, Gerresheimer operates dedicated vial lines across Europe, North America, and Asia, with end-to-end capabilities from glass tubing to ready-to-use depyrogenated formats. The company's investments in pharma-grade coating technologies and digital quality tracking differentiate its premium offerings.

• SCHOTT: Renowned for its FIOLAX and SCHOTT Mio glass tubing platforms, SCHOTT supplies both raw tubing and finished vials to global pharmaceutical manufacturers. The company's focus on ultra-clean pharmaceutical glass and its EVERIC pure product line addresses the growing sensitivity of biologic formulations to extractables.

• Stevanato Group: An integrated provider of glass primary packaging and drug delivery systems, Stevanato Group has differentiated through its EZ-fill ready-to-use vial platform, enabling pharmaceutical clients to bypass in-house washing and depyrogenation steps. Its Engineering Division also supplies filling and inspection equipment.

• DWK Life Sciences: Operating the WHEATON and KIMBLE brands, DWK Life Sciences serves laboratory and pharmaceutical markets with a broad portfolio of glass vials, including depyrogenated formats for clinical and compounding applications. The company competes on product breadth and technical service support.

• Nipro Pharma Packaging: A subsidiary of Nipro Corporation, this entity specializes in pharmaceutical glass containers including ampoules and vials, with manufacturing footprints in Europe and Asia. Its cost-competitive positioning serves both innovator and generic drug manufacturers.

• Corning Incorporated: Through its Valor Glass platform, Corning has introduced an aluminosilicate glass vial with enhanced chemical durability and resistance to delamination, targeting high-value biologic formulations where traditional borosilicate glass shows performance limitations.

• Thermo Fisher Scientific Inc.: A major distributor and manufacturer of laboratory-grade vials, Thermo Fisher Scientific Inc. serves the clinical laboratory and compounding pharmacy segments with certified sterile and depyrogenated glass and plastic vials, leveraging its global distribution network.

• Merck KGaA: Through its MilliporeSigma division, Merck KGaA supplies specialty glass vials and closures to the biopharmaceutical research and manufacturing community, with strong technical support capabilities for formulation scientists.

• VWR International: A broad-line scientific distributor now integrated within Avantor, VWR International provides depyrogenated vials to academic, clinical, and industrial research customers, competing primarily on procurement convenience and catalog depth.

• APG Pharma: A specialist in pharmaceutical primary packaging components, APG Pharma focuses on glass vials, ampoules, and cartridges, with particular strength in European markets and growing presence in emerging economies.

• Radpharm Scientific: A regional player serving radiopharmaceutical and clinical laboratory markets, Radpharm Scientific provides specialized sterile vial formats adapted for radioactive and short-shelf-life diagnostic compound filling.

Recent Developments & Milestones in the Depyrogenated Sterile Empty Vials Market

• January 2024: Stevanato Group announced the expansion of its EZ-fill ready-to-use vial production capacity at its Piombino Dese facility in Italy, adding two automated depyrogenation and packaging lines to meet accelerating biologic drug manufacturer demand, representing a capital investment exceeding €40 million.

• March 2024: SCHOTT AG received FDA Drug Master File (DMF) acceptance for its EVERIC pure Type I+ glass vial line, enabling pharmaceutical customers to reference the DMF in NDA and ANDA submissions and reducing their individual qualification burden.

• June 2023: Gerresheimer completed the acquisition of Bormioli Pharma's glass vial manufacturing assets in Italy, consolidating production capacity and expanding its southern European footprint by approximately 1.2 billion units of annual vial output.

• September 2023: Corning Incorporated entered into a long-term supply agreement with a major U.S.-based mRNA therapeutics developer to provide Valor Glass vials qualified for lipid nanoparticle (LNP) formulations, marking a strategic entry into next-generation vaccine and gene therapy packaging.

• November 2023: The revised EU GMP Annex 1 on Manufacture of Sterile Medicinal Products became fully enforceable, requiring all manufacturers supplying sterile vials to EU-market pharmaceutical companies to demonstrate compliance with enhanced contamination control strategy (CCS) documentation requirements.

• February 2024: Nipro Pharma Packaging inaugurated a new ISO Class 7 cleanroom depyrogenation facility in Olomouc, Czech Republic, targeting European biosimilar manufacturers seeking locally qualified packaging supply chains.

• April 2024: Thermo Fisher Scientific Inc. launched an expanded portfolio of ready-to-use depyrogenated vials in 10 mL and 20 mL formats specifically designed for oncology combination therapy applications requiring multi-component fill operations.

Regional Market Breakdown for the Depyrogenated Sterile Empty Vials Market

The Depyrogenated Sterile Empty Vials Market exhibits pronounced regional heterogeneity in both growth rates and demand composition, reflecting structural differences in pharmaceutical manufacturing maturity, regulatory frameworks, and healthcare spending trajectories.

North America represents the most mature and highest-value regional market, accounting for an estimated 34–36% of global revenue in 2023, equivalent to approximately $255–$270 million. The United States dominates the regional share, driven by the world's largest concentration of biopharmaceutical manufacturing sites, a prolific CDMO sector, and robust biologics commercialization activity. The regional CAGR is estimated at 6.8–7.2%, slightly below the global average, reflecting market maturity rather than demand deceleration. Key demand drivers include the continued growth of the biosimilar market following patent expirations of multiple blockbuster biologics, and sustained investment in domestic vaccine fill-finish resilience following COVID-19 supply chain vulnerabilities.

Europe accounts for approximately 28–30% of global revenue, with Germany, France, Italy, and the United Kingdom representing the leading national markets. The enforcement of the revised EU GMP Annex 1 in November 2023 has accelerated qualification activities and near-term vial procurement as manufacturers upgrade their primary packaging supply chains to meet new contamination control documentation requirements. The regional CAGR is estimated at 6.5–7.0%, supported by a strong biosimilar manufacturing base and growing orphan drug pipeline activity.

Asia Pacific is the fastest-growing region, with an estimated CAGR of 9.5–10.2%, significantly above the global average. China and India are the primary growth engines, driven by expanding domestic pharmaceutical manufacturing capacity, government-mandated quality upgrades, and increasing contract manufacturing activity for global innovator companies. Japan and South Korea contribute through their advanced biologics sectors. The region's share is projected to expand from approximately 22% in 2023 to nearly 28% by 2033 as local manufacturers invest in compliant depyrogenation infrastructure.

Latin America, led by Brazil and Argentina, holds approximately 6–7% of global market share, with a regional CAGR of 7.5–8.0% driven by expanding domestic pharmaceutical production and rising injectable drug consumption. The Middle East and Africa region, while currently representing less than 5% of global value, is experiencing accelerating demand tied to healthcare infrastructure investment in GCC countries and

Depyrogenated Sterile Empty Vials Market Segmentation

• 1. Material
  • 1.1. Plastic
  • 1.2. Glass
• 2. Volume
  • 2.1. 2 ml
  • 2.2. 5 ml
  • 2.3. 10 ml
  • 2.4. 20 ml
  • 2.5. More than 20 ml
• 3. End user
  • 3.1. Clinical labs
  • 3.2. Compounding labs
  • 3.3. Pharma and Biotech companies
  • 3.4. Other (Contract manufacturing organizations (CMO

Depyrogenated Sterile Empty Vials Market Segmentation By Geography

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific